This is the first time Biocartis has collaborated with Wellcome Trust Sanger Institute and Philips Research. Ultimately, the test they design is envisioned as being broadly applicable for all types of solid, metastatic tumors, according to Nader Donzel, chief technology officer at Biocartis and head of its DMAT business unit. DMAT, which stands for Dynamic Multi-Analyte Technology, is the codename of Biocartis' Multiplex Assay Platform, which enables accelerated development of multi- analyte assays, reduces time-to-result and hands-on time, and provides high-quality protein and nucleic acid-based biomarker analysis.

 

"From a timing perspective, this collaboration is well placed in the sense that as a company, you find yourself at a juncture—as we are now—where you feel that your technology offers significant advantages over existing technology, but you don't have the full package of funding, data or support that you need," Donzel tells ddn. "So, coming into this collaboration was an excellent way to demonstrate and validate Biocartis' claims of its technology and have access to patient samples and expanded opportunities. For the other partners, it opens for them a clinical perspective that they cannot achieve with other technologies and offers them a new way of looking at the solutions that can get them faster and better clinical data."